Comparison of Different Pulsed Field Ablation Catheters Combined With Stroke Prevention in High Stroke Risk·Atrial Fibrillation: A Prospective, Multicenter, Randomized Controlled Trial

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Pulsed field energy ablation, a non-thermal ablation modality, can potentially reduce post-ablation tissue edema. Previous studies have confirmed the feasibility and safety of combined pulsed field ablation (PFA) and left atrial appendage closure (LAAC) as a one-stop treatment, with few reports of post-ablation tissue edema. However, during PFA procedures, the presence of metallic components in the ablation site (e.g., occluder frames, metallic valves) may lead to arcing during energy delivery, compromising procedural safety. Therefore, when performing PFA+LAAC as a one-stop procedure, a ablation-first strategy is recommended. Due to the influence of parameters such as voltage, pulse width, and number of cycles on pulsed field energy characteristics, significant variability in ablation depth and area may exist between different PFA devices. To date, no large-scale clinical studies have compared the efficacy and safety of different PFA systems. Accordingly, this study will conduct a prospective, multicenter, randomized controlled trial to compare the effectiveness and safety of domestic versus imported pulsed field ablation catheters in the treatment of patients with atrial fibrillation.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 118
Healthy Volunteers: f
View:

• Older than 18 years.

• Diagnosed with drug-refractory, symptomatic atrial fibrillation.

• The patient has a high risk of stroke (CHA2DS2-VA score ≥ 2).

• Have a situation of:

‣ requires oral anticoagulation therapy

⁃ high bleeding risk (HAS-BLED score ≥ 3) that unsuitable for or unwilling to undergo long-term oral anticoagulation therapy.

• Subjects are able to understand the purpose of the study, voluntarily participate in the study and sign the informed consent, and are willing to complete the follow-up according to the requirements of the program.

Locations
Other Locations
China
Ningbo First Hospital
RECRUITING
Hangzhou
Contact Information
Primary
Huimin Chu, Dorctor
epnbheart@163.com
+86 574-87085211
Time Frame
Start Date: 2025-06-30
Estimated Completion Date: 2031-06-30
Participants
Target number of participants: 292
Treatments
Experimental: CardiPulse Group
Patients accept atrial fibrillation ablation with CardiPulse pulsed field ablation catheter
Active_comparator: FaraPulse Group
Patients accept atrial fibrillation ablation with FaraPulse pulsed field ablation catheter
Related Therapeutic Areas
Sponsors
Leads: Hangzhou Dinova EP Technology Co., Ltd

This content was sourced from clinicaltrials.gov